Raising awareness for DIPG

Childhood Brain Cancer Awareness Day aims to increase community awareness of all childhood brain cancers and bring together key childhood and brain cancer groups, non-government organisations (NGOs) and charities to work cohesively to increase research funding and improve outcomes for childhood brain cancer.

The inaugural Childhood Brain Cancer Awareness Day will commence 26 September 2019, and will have a focus on Diffuse Intrinsic Pontine Glioma (DIPG), with a different childhood brain cancer to be selected as a focus for each subsequent year.

"Australia is one of the wealthiest nations per capita in the world and there is no reason why we should not be leading the way with government funding for children’s medical research." - Karl Fretwell, father of Brooke Fretwell.

Childhood Brain Cancer Awareness Day is made possible through collaboration with Cancer Australia, Love for LachieRun DIPG, Robert Connor Dawes Foundation, Australia New Zealand Children’s Haematology/Oncology Group, Children’s Cancer Institute, Children’s Hospital Foundation, Isabella and Marcus Foundation, Children’s Cancer Foundation and Brain Child Foundation.

 

Josie-Dun-820x460.png

Brooke's story: "How many tears?"

For the six months following the death of their 15-year-old daughter Brooke, parents Karl and Olivia Fretwell entered a difficult period in their relationship. The last 13 years had been spent in a bubble, caring for young Brooke since her first brain cancer diagnosis. When the journey ended with tragedy, they realised the experience had taken its toll.

Our research projects

DIPG is the most agressive cancer to affect children, with no known curative therapies. Innovative treatment approaches are urgently needed. We are proud to fund a number of research projects around Australia. You can learn more about childhood brain cancer via Cancer Australia

Synthetic retinoid therapy for diffuse intrinsic pontine glioma 

Through vigorous testing, Associate Professor Ziegler and his team discovered fenretinide, a synthetic drug related to vitamin A, could be effective in treating DIPG.

3D printers and
mini-brains

Associate Professor O’Neill’s team aim to use new techniques to ‘print’ brain tumours in gels with the same soft consistency as brain and, separately, to grow ‘mini-brains’ from human stem cells.

Epigenetic targeted
therapy in DIPG

The first in Australia to establish and run a dedicated DIPG research program with an extensive bank of tissue, cell cultures and in vivo models that provide a unique facility to investigate innovative therapies.

Sign up for the symposium

Go gold for kids with cancer

The Kids' Cancer Project is an ACNC Registered Charity 
ABN 13 061 138 181 | CFN 10581